Evidence map›Paper›PMID 38997232›Full record

ArticleAngewandte Chemie (International ed. in English)2024

Indazole to 2-Cyanoindole Scaffold Progression for Mycobacterial Lipoamide Dehydrogenase Inhibitors Achieves Extended Target Residence Time and Improved Antibacterial Activity.

Shan Sun, John Ginn, Tomasz Kochanczyk, Nancy Arango, Xiuju Jiang, David J Huggins, James Bean, Mayako Michino, Leigh Baxt, Nigel Liverton and 2 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shan SunSanders Tri-Institutional Therapeutics Discovery Institute, Bronk Laboratory, 1230 York Avenue, Box 122, New York, NY 10065, USA.
John GinnSanders Tri-Institutional Therapeutics Discovery Institute, Bronk Laboratory, 1230 York Avenue, Box 122, New York, NY 10065, USA.
Tomasz KochanczykStructural Biology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Nancy ArangoStructural Biology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Xiuju JiangDepartment of Microbiology and Immunology, Weill Cornell Medicine, 413 East 69 Street, New York, NY 10021, USA.
David J HugginsSanders Tri-Institutional Therapeutics Discovery Institute, Bronk Laboratory, 1230 York Avenue, Box 122, New York, NY 10065, USA.
James BeanImmunology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Mayako MichinoSanders Tri-Institutional Therapeutics Discovery Institute, Bronk Laboratory, 1230 York Avenue, Box 122, New York, NY 10065, USA.
Leigh BaxtSanders Tri-Institutional Therapeutics Discovery Institute, Bronk Laboratory, 1230 York Avenue, Box 122, New York, NY 10065, USA.
Nigel LivertonSanders Tri-Institutional Therapeutics Discovery Institute, Bronk Laboratory, 1230 York Avenue, Box 122, New York, NY 10065, USA.
Peter T MeinkeSanders Tri-Institutional Therapeutics Discovery Institute, Bronk Laboratory, 1230 York Avenue, Box 122, New York, NY 10065, USA.
Ruslana BrykDepartment of Microbiology and Immunology, Weill Cornell Medicine, 413 East 69 Street, New York, NY 10021, USA.ORCID 0000-0002-2179-671X

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Studies of lipoamide dehydrogenase tight binding inhibition in tuberculous and non-tuberculous mycobacteriaR01AI175342 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Ruslana Bryk · 2024 to 2026
$1.8M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases AI175342NCI NIH HHS P30 CA008748NCI NIH HHS P30CA008748NIAID NIH HHS R01 AI175342
6 · The paper itself

Abstract

Tuberculosis remains a leading cause of death from a single infection worldwide. Drug resistance to existing and even new antimycobacterials calls for research into novel targets and unexplored mechanisms of action. Recently we reported on the development of tight-binding inhibitors of Mycobacterium tuberculosis (Mtb) lipoamide dehydrogenase (Lpd), which selectively inhibit the bacterial but not the human enzyme based on a differential modality of inhibitor interaction with these targets. Here we report on the striking improvement in inhibitor residence time on the Mtb enzyme associated with scaffold progression from an indazole to 2-cyanoindole. Cryo-EM of Lpd with the bound 2-cyanoindole inhibitor 19 confirmed displacement of the buried water molecule deep in the binding channel with a cyano group. The ensuing hours-long improvement in on-target residence time is associated with enhanced antibacterial activity in axenic culture and in primary mouse macrophages. Resistance to 2-cyanoindole inhibitors involves mutations within the inhibitor binding site that have little effect on inhibitor affinity but change the modality of inhibitor-target interaction, resulting in fast dissociation from Lpd. These findings underscore that on-target residence time is a major determinant of antibacterial activity and in vivo efficacy.

Indexed as

Dihydrolipoamide DehydrogenaseIndazolesIndolesMycobacterium tuberculosisAnimalsAnti-Bacterial AgentsAntitubercular AgentsEnzyme InhibitorsHumansMiceMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipAnti-Bacterial AgentsAntitubercular AgentsDihydrolipoamide DehydrogenaseEnzyme InhibitorsIndazolesIndoleslipoamide dehydrogenasemycobacteriaon-target residence timetight binding inhibitortuberculosis

Identifiers

PMID38997232
PMCPMC11887847

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.